Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
The combination of ibrutinib and venetoclax represents the first fixed-duration oral treatment involving a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor for adult patients with untreated chronic lymphocytic leukaemia. The phase 2 CAPTIVATE and phase 3 GLOW clinical studies served as the basi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2025-01-01
|
| Series: | Acta Haematologica Polonica |
| Subjects: | |
| Online Access: | https://journals.viamedica.pl/acta_haematologica_polonica/article/view/105572 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|